Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.

Cytotoxic T-cell (CTL) cultures were generated from five ovarian cancer patients (OvCTL) and from three breast cancer patients (BrCTL). All CTL lines were T-cell receptor (TcR) alphabeta+ and predominantly CD8+ (73 +/- 13%). These CTL lines preferentially recognized autologous tumor cells in an HLA class I-restricted, and in part HLA-A2-restricted, manner. In addition, the CTL lines recognized allogeneic HLA-A2+ ovarian and breast tumor cells. Specific recognition was determined by T-cell-mediated cytotoxicity as well as cytokine release. Coculture of irradiated autologous tumor cells with OvCTL induced secretion of IFN-gamma, GM-CSF and TNF-alpha, but not IL-4, indicating a T helper-1-type response. Similar results were obtained when OvCTL and BrCTL were stimulated with histologically matched HLA-A2+ tumor cells. Also, BrCTL stimulated with HLA-A2+ but not HLA-A2- ovarian tumor cells produced significant levels of GM-CSF and TNF-alpha. Finally, the Her2/neu peptide p654-662, earlier identified as a tumor antigen in both ovarian and breast cancer, induced cytotoxicity as well as the specific release of IFN-gamma and TNF-alpha but not IL-4 by OvCTL and BrCTL. Thus, tumor-specific recognition by CTL was verified by cytotoxicity and cytokine release. The secretion of Th1-like cytokines as opposed to Th2-like cytokines suggest that therapeutically OvCTL and BrCTL could potentially enhance the endogenous immune response to tumor.

[1]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[2]  T. Eberlein,et al.  Shared T cell epitopes in epithelial tumors. , 1995, Cellular immunology.

[3]  T. Eberlein,et al.  Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Coulie,et al.  From defined human tumor antigens to effective immunization? , 1995, Immunology today.

[5]  T. Eberlein,et al.  Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer. , 1995, Surgery.

[6]  T. Eberlein,et al.  In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. , 1995, Surgical oncology.

[7]  T. Eberlein,et al.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Gazdar,et al.  HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. , 1994, Cancer research.

[9]  S. Rosenberg,et al.  Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.

[10]  T. Eberlein,et al.  Classification of CD4+ T helper cell clones in human melanoma. , 1994, Cellular immunology.

[11]  T. Eberlein,et al.  TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. , 1994, Journal of immunology.

[12]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[13]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Eberlein,et al.  Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. , 1994, Surgical oncology.

[15]  E. Klein,et al.  Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[16]  R. Freedman,et al.  Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. , 1993, Lymphokine and cytokine research.

[17]  T. Eberlein,et al.  HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. , 1993, Journal of immunology.

[18]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[19]  S. Rosenberg,et al.  Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[20]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[21]  J. Wharton,et al.  Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. , 1991, Cancer research.

[22]  S. Rosenberg,et al.  Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.

[23]  S. Rosenberg,et al.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes , 1991, The Journal of experimental medicine.

[24]  A. Anichini,et al.  Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? , 1990, Journal of the National Cancer Institute.

[25]  S. Dubinett,et al.  TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER , 1989, The Lancet.

[26]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[27]  W. Linehan,et al.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Eberlein,et al.  T-cell recognition of ovarian cancer. , 1993, Surgery.

[29]  S. Rosenberg,et al.  Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.